生物活性 | Semaglutide TFA, a long-actingGLP-1analogue, is a glucagon-like peptide-1(GLP-1)receptor agonist. Semaglutide TFA has the potential for type 2 diabetes treatment. | ||||||||||||||||
IC50& Target | GLP-1 receptor[1]. | ||||||||||||||||
体外研究 (In Vitro) | Semaglutide has two amino acid substitutions compared to human GLP-1 (Aib8, Arg34) and is derivatized at lysine 26. The GLP-1R affinity of Semaglutide is 0.38±0.06 nM[1]. Semaglutide is a GLP-1 analogue with 94% sequence omology to human GLP-1[3. | ||||||||||||||||
体内研究 (In Vivo) | The plasma half-life of Semaglutide is 46h in mini-pigs following i.v. administration and semaglutide has an MRT of 63.6h after s.c. dosing to mini-pigs[1]. Semaglutide improves 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP)-induced motor impairments. In addition, Semaglutide rescues the decrease of tyrosine hydroxylase (TH) levels, alleviates the inflammation response, reduces lipid peroxidation, inhibits the apoptosis pathway, and also increases autophagy- related protein expression, to protect dopaminergic neurons in the substantia nigra and striatum. Moreover, the long-acting GLP-1 analogue semaglutide is superior to liraglutide in most parameters[2]. Semaglutide lowers blood glucose by stimulating the release of insulin and also lowers body weight[3]. | ||||||||||||||||
Clinical Trial | |||||||||||||||||
分子量 | 4227.66 | ||||||||||||||||
性状 | Solid | ||||||||||||||||
Formula | C189H292F3N45O61 | ||||||||||||||||
中文名称 | 索马鲁肽三氟乙酸 | ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 | Sealed storage, away from moisture
*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) | ||||||||||||||||
溶解性数据 | In Vitro: DMSO : 100 mg/mL(23.65 mM;ultrasonic and warming and heat to 60℃) H2O : 100 mg/mL(23.65 mM;Need ultrasonic) 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 |
维奥蛋白资源库 - 中文蛋白资源 CopyRight © 2010-2024 |